Lundbeck: Nalmefene completes clinical phase III programme
Submission of the European Marketing Authorization Application (MAA) is expected by the end of 2011
17-Jun-2011 -
H. Lundbeck A/S announced the completion of the final study (ESENSE2) in the phase III clinical programme for nalmefene in patients with alcohol dependence. In this multi-center, double-blind, placebo-controlled study, 718 individuals were randomized to receive oral administration of 20 mg of ...
alcohol dependence
European Marketing Authorization Application
Lundbeck
+2